H.I.G. Capital acquires pharmacy tech firm Outcomes, reaching 85% of US pharmacies
What's the deal? H.I.G. CapitalDealroom has a profile for this one. Try Dealroom →, a Miami-based alternative investment firm with $75 billion under management, has acquired Outcomes OneDealroom has a profile for this one. Try Dealroom →, an Orlando-based provider of clinical network services and pharmacy technology. Terms were not disclosed.
What does OutcomesDealroom has a profile for this one. Try Dealroom → do? It connects roughly 85% of US pharmacies through a national network, enabling pharmacist-delivered clinical interventions and medication-based care. It also sells pharmacy management software and workflow automation tools that handle prescription processing, dispensing, billing, and inventory.
By the numbers: In 2025, Outcomes facilitated more than 10 million clinical interventions across 130 million covered lives. Its customers span national and regional chains, health systems, specialty and long-term care providers, and independent community pharmacies.
What's the endgame? H.I.G. plans to back Outcomes' pharmacist-led clinical network and technology platforms, including Rx30Dealroom has a profile for this one. Try Dealroom →, Computer-RxDealroom has a profile for this one. Try Dealroom →, and Outcomes PremiumDealroom has a profile for this one. Try Dealroom →. "Our partnership with H.I.G. will provide additional resources and expertise to continue investing in our unique pharmacist-led clinical network," said Jude Dieterman, chief executive officer of Outcomes.
Why does it matter? H.I.G.'s equity funds target management buyouts, recapitalisations, and corporate carve-outs of middle market companies. Arjun Mohan, a managing director at the firm, said the deal supports Outcomes' aim of "elevating the role of pharmacies in the healthcare system."
H.I.G. was advised by William Blair & Co.Dealroom has a profile for this one. Try Dealroom → and Kirkland & EllisDealroom has a profile for this one. Try Dealroom →. Outcomes was advised by TripleTreeDealroom has a profile for this one. Try Dealroom → and Simpson Thacher & Bartlett.
The signal: The deal underscores private equity's appetite for healthcare infrastructure that sits between pharmacies, health plans, and drug manufacturers — assets that combine broad network reach with recurring software revenue.
Image credit: Generated with Gemini
